August 8, 2024 07:59 AM EDT

Entero Therapeutics turns the lights off as creditors come calling

Amber Tong

Just months after Entero Therapeutics completed the merger that brought in its new lead candidate, the debt inherited from the deal is creeping up on …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Entero Therapeutics turns the lights off as creditors come calling

Amber Tong

Sign up to read this article for free.

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

Amgen names Stanford geneticist and biotech founder to CSO post

NewAmsterdam aces Phase 3 trial, but investors are skeptical

FDA updates label of 33-year-old cancer drug with new dose and warning

Post-Hoc: RFK vs. Vivek, and the future of US drug policy

Are programs with compounded GLP-1s safe for your population?

En­tero Ther­a­peu­tics turns the lights off as cred­i­tors come call­ing

Amber Tong

Sign up to read this article for free.

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Entero Therapeutics turns the lights off as creditors come calling

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

Amgen names Stanford geneticist and biotech founder to CSO post

NewAmsterdam aces Phase 3 trial, but investors are skeptical

FDA updates label of 33-year-old cancer drug with new dose and warning

Post-Hoc: RFK vs. Vivek, and the future of US drug policy

Are programs with compounded GLP-1s safe for your population?